Nurix taps Roche in multibillion-dollar bexobrutideg deal
Bottom line
Nurix Therapeutics said on June 8, 2026, that it has signed a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, an investigational oral BTK degrader formerly known as NX-5948. The deal brings Nurix $700 million upfront and could be worth up to $2.3 billion more in development, regulatory, and sales milestones, with the companies sharing U.S. profits and losses equally and Nurix receiving royalties outside the U.S. The partners said they plan to advance bexobrutideg not only in malignant hematology, including chronic lymphocytic leukemia, but also into immunology and neurology, with Phase 2 studies planned in chronic spontaneous urticaria and multiple sclerosis. (globenewswire.com)
Why it matters: For veterinary professionals, this is mostly a market and platform story rather than a practice-changing one. Still, it’s notable because Roche is making a large bet on targeted protein degradation, a drug design approach meant to remove disease-driving proteins rather than simply inhibit them. Bexobrutideg is already in a pivotal Phase 2 study in relapsed or refractory CLL and is slated for a Phase 3 trial in summer 2026 against pirtobrutinib, suggesting Roche sees enough potential in the BTK degrader class to back late-stage development across oncology, immunology, and neurology. (ir.nurixtx.com)
What to watch: Watch for the Phase 3 CLL launch in summer 2026, any antitrust clearance milestones tied to the collaboration becoming fully effective, and early signals on whether Roche and Nurix can expand bexobrutideg beyond blood cancers into immune-mediated disease. (globenewswire.com)
Nurix Therapeutics has landed one of the larger biotech partnering deals of the year, announcing on June 8, 2026, a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, its investigational oral Bruton’s tyrosine kinase, or BTK, degrader. The agreement gives Nurix $700 million upfront, with the potential for up to $2.3 billion in additional milestones, while setting up a 50-50 U.S. profit-and-loss split and ex-U.S. royalties for Nurix. Roche framed the deal as a way to deepen its hematology pipeline while also opening expansion opportunities in immunology and neurology. (globenewswire.com)
The backdrop is Nurix’s multiyear effort to position bexobrutideg, previously called NX-5948, as a next-generation alternative to BTK inhibitors in B-cell malignancies. In April, the company said it was already running the pivotal DAYBreak CLL-201 Phase 2 study in relapsed or refractory chronic lymphocytic leukemia and planned to start a global confirmatory Phase 3 trial by mid-2026. That Phase 3 study is designed to compare bexobrutideg with pirtobrutinib in patients whose disease progressed after prior BTK inhibitor therapy. Earlier company updates also highlighted preclinical data suggesting broad coverage of clinically relevant BTK resistance mutations and selective degradation of the target protein. (ir.nurixtx.com)
Under the new partnership, the development plan broadens well beyond CLL. Nurix and Roche said they intend to pursue multiple label-enabling studies across malignant hematology, including monotherapy and combination regimens, while also moving into immune-mediated disease and neurology. Specifically, the companies named planned Phase 2 trials in multiple sclerosis and chronic spontaneous urticaria. Roche said the degrader approach could potentially overcome resistance mechanisms seen with standard BTK inhibitors, a key commercial and clinical rationale in crowded B-cell malignancy markets. (globenewswire.com)
Financially, the structure is significant for a clinical-stage biotech. Nurix gets a large non-dilutive cash infusion at a time when it had previously outlined plans to fund a broad registrational program and expand into immunology and inflammation. The company had said in April that healthy volunteer studies with a tablet formulation were intended to support an IND filing and enable expansion into immunology and inflammation indications in 2026. The new Roche alliance effectively accelerates and de-risks that strategy by adding a large pharma partner with global development and commercialization infrastructure. (ir.nurixtx.com)
Early industry reaction has focused on the size of Roche’s upfront commitment and the competitive setup in CLL. Fierce Biotech reported that Roche is betting $700 million upfront on a late-phase BTK degrader that is expected to face Eli Lilly’s Jaypirca, the brand name for pirtobrutinib, in Phase 3. That framing underscores how the deal is being read: not as a discovery-stage option agreement, but as a high-conviction move around an asset nearing a pivotal head-to-head test in a validated market. (fiercebiotech.com)
Why it matters: For veterinary professionals, this isn’t a companion animal therapeutics story, but it is relevant as a signal of where biopharma capital is moving. Large cross-indication deals like this can shape R&D priorities, talent movement, and platform validation across the life sciences sector, including areas adjacent to veterinary oncology and immunology. The bigger takeaway is that targeted protein degradation continues to attract major investment as companies look for ways to address resistance, tolerability, and tissue penetration challenges that conventional inhibitors may not solve as well. (globenewswire.com)
There are also execution risks to watch. Nurix’s disclosure notes the collaboration is subject to regulatory review, including under the Hart-Scott-Rodino Act, and the company flagged the operational demands of funding 40% of development costs across multiple trials and building or maintaining a U.S. commercialization organization. In other words, the headline number is large, but success will depend on trial readouts, regulatory timing, and whether the partners can make a shared-commercialization model work. (marketscreener.com)
What to watch: The next milestones are likely to be the formal Phase 3 CLL start in summer 2026, any additional data presentations from the ongoing NX-5948-301 and DAYBreak programs, and confirmation that the Roche collaboration clears antitrust review and becomes fully operational on schedule. (ir.nurixtx.com)